Recovery of reproductive function in rats treated with the aromatase inhibitor fadrozole

Reproductive Toxicology

Volumn 10, Issue 5, 1996, Pages 373-377

  Nunez, Susan B ^a,d   Blye, Richard P ^a   Thomas, Pamela M ^a,c   Reel, Jerry R ^b   Barnes, Kevin M ^a   Malley, James D ^a   Cutler Jr , Gordon B ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b BIOQUAL INC   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

aromatase inhibitor; estrous cycles; fadrozole hydrochloride; fertility; gestational body weight; gynecomastia; McCune Albright syndrome; reproductive toxicology

Indexed keywords

ANIMALIA;

EID: 0030250888     PISSN: 08906238     EISSN: None     Source Type: Journal    
DOI: 10.1016/0890-6238(96)00083-4     Document Type: Article

References (12)

1. 1. Feuillan PP, Foster CM, Pescovitz OH, Hench KD, Shawker T, Dwyer A, Malley JD, Barnes K, Loriaux DL, Cutler GB Jr. Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone. N Engl J Med. 1986; 315:1115-9.
2. 2. Feuillan PP, Jones J, Cutler GB Jr. Long term testolactone therapy for precocious puberty in girls with the McCune-Albright syndrome. J Clin Endocrinol Metab. 1993;77:647-51.
3. 3. Steele RE, Mellor LB, Sawyer WK, Wasvary JM, Browne LJ. In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor, CGS 16949A. Steroids. 1987;50:147-61.
4. 4. Bhatnagar AS, Häuslaer A, Schieweck K, Browne LJ, Bowman R, Steele RE. Novel aromatase inhibitors. J Steroid Biochem Mol Biol. 1990;37:363-7.
5. 5. Santen RJ, Demers LM, Adlercreutz H, Harvey H, Santner S, Sanders S, Lipton A. Inhibition of aromatase with CGS 16949A in postmenopausal women. J Clin Endocrinol Metab. 1989;68:99-106.
6. 6. Stein RC, Dowsett M, Davenport J, Medley A, Ford HT, Gazet J-C, Coombes RC. Preliminary study of the treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor CGS 16949A. Cancer Res. 1990;50:1381-4.
7. 7. Lipton A, Harvey HA, Demers LM, Hanagan JR, Mulagha MT, Kochak GM, Fitzsimmons S, Sanders SI, Santen RJ. A phase I trial of CGS 16949A - A new aromatase inhibitor. Cancer. 1990;65: 1279-85.
8. 8. Sundaram K, Didolkar A, Keizer-Zucker A, DeJesus W, Rivier J, Vale W, Bardin CW. A 90-d subcutaneous toxicity and fertility study of a LHRH antagonist in rats. Fundam Appl Toxicol. 1990; 14:734-44.
9. 9. Bonsall RW, Clancy AN, Michael RP. Effects of the nonsteroidal aromatase inhibitor, fadrozole, on sexual behaviour in male rats. Horm Behav. 1992;26:240-54.
10. 10. Zumpe D, Bonsall RW, Michael RP. Effects of the nonsteroidal aromatase inhibitor, fadrozole on the sexual behaviour of male cynomolgus monkeys (Macaca fascicularis). Horm Behav. 1993; 27:200-15.
11. 11. Laue L, Jones J, Barnes KM, Cutler GB, Jr. Treatment of familial male precocious puberty with spironolactone, testolactone, and deslorelin. J Clin Endocrinol Metab. 1993;76:151-5.
12. 12. Zachmann M, Eiholzer U, Muritano M. Werder EA, Manella B. Treatment of pubertal gynaecomastia with testolactone. Acta Endocrinol Suppl (Copenh). 1986;279:218-26.